India’s coronavirus cases jump, transmission rate increases

1 / 3
Talla Vijaya Lakshmi, a tailor stitches face masks in her temporary shop on the roadside in Hyderabad on July 9, 2020. (AFP)
2 / 3
Medical volunteers wearing Personal Protective Equipment (PPE) gear take temperature reading of a woman as they conduct a door-to-door medical screening inside Dharavi slums to fight against the spread of the COVID-19 coronavirus, in Mumbai on July 9, 2020. (AFP)
3 / 3
Medical volunteers wear Personal Protective Equipment (PPE) gear before conducting a door-to-door medical screening inside Dharavi slums to fight against the spread of the COVID-19 coronavirus, in Mumbai on July 9, 2020. (AFP)
Short Url
Updated 09 July 2020

India’s coronavirus cases jump, transmission rate increases

  • The new cases bring the total in the world’s third worst-affected country to 767,296
  • Health experts say the true extent of the virus’s spread in India is unknown and more testing must be done

NEW DELHI: India reported nearly 25,000 new coronavirus infections Thursday and its transmission rate is increasing for the first time since March.
The new cases bring the total in the world’s third worst-affected country to 767,296. India’s health ministry said the COVID-19 death toll had risen to 21,129.
Research by the Institute of Mathematical Sciences in Chennai shows that India’s virus reproduction rate ticked up in the first week of July to 1.19 after steadily falling from peak transmission of 1.83 in March. The rate needs to be below one for new cases to start falling.
India’s infection numbers have skyrocketed since lockdown restrictions were eased. At the same time, testing has ramped up to more than 200,000 samples a day, compared to just a few hundred in March.
Health experts say the true extent of the virus’s spread in India is unknown and more testing must be done, given its population of nearly 1.4 billion people.


US to pay over $1bn for 100m doses of J&J’s potential COVID-19 vaccine

Updated 13 min 30 sec ago

US to pay over $1bn for 100m doses of J&J’s potential COVID-19 vaccine

  • The latest contract equates to roughly $10 per vaccine dose produced by J&J
  • This is J&J’s first deal to supply its investigational vaccine to a country

WASHINGTON: The United States government will pay Johnson & Johnson over $1 billion for 100 million doses of its potential coronavirus vaccine, its latest such arrangement as the race to tame the pandemic intensifies, the drugmaker said on Wednesday.
It said it would deliver the vaccine to the Biomedical Advanced Research and Development Authority (BARDA) on a not-for-profit basis to be used after approval or emergency use authorization by the US Food and Drug Administration (FDA).
J&J has already received $1 billion in funding from the US government — BARDA agreed in March to provide that money for the company to build manufacturing capacity for more than 1 billion doses of the experimental vaccine.
The latest contract equates to roughly $10 per vaccine dose produced by J&J. Including the first $1 billion deal with the USgovernment, the price would be slightly higher than the $19.50 per dose that the United States is paying for the vaccine being developed by Pfizer Inc. and German biotech BioNTech SE.
The US government may also purchase an additional 200 million doses under a subsequent agreement. J&J did not disclose that deal’s value.
J&J plans to study a one- or two-dose regimen of the vaccine in parallel later this year. A single-shot regimen could allow more people to be vaccinated with the same number of doses and would sidestep issues around getting people to come back for their second dose.
This is J&J’s first deal to supply its investigational vaccine to a country. Talks are underway with the European Union, but no deal has yet been reached.
J&J’s investigational vaccine is currently being tested on healthy volunteers in the United States and Belgium in an early-stage study.
There are currently no approved vaccines for COVID-19. More than 20 are in clinical trials.